Anam Ashraf | Structural Biology | Women Researcher Award

Published on by Molecular Biologist

Dr. Anam Ashraf | Structural Biology | Women Researcher Award 

DHR Young Scientist, at Jamia Millia Islamia, India.

Dr. Anam Ashraf is a dynamic and accomplished researcher with a Ph.D. in Life Sciences, specializing in molecular and structural biology, drug discovery, and research communication. Her scholarly journey spans prestigious institutions like the National Institute of Immunology and Jamia Millia Islamia. With a flair for both benchwork and penwork, Dr. Ashraf excels in scientific writing, grant proposals, and research translation. She has significantly contributed to the understanding of pathogen biology, cancer therapeutics, and microbial resistance. Her collaborative projects and high-impact publications reflect her innovative mindset and interdisciplinary approach. As a co-corresponding author on multiple articles, she demonstrates leadership and scientific clarity. Dr. Ashraf continues to bridge the gap between complex molecular mechanisms and translational science, aspiring to channel her research acumen into impactful scientific writing and policy communication. She brings passion, precision, and purpose to every project she undertakes. 📚💡

Professional Profile

Scopus

ORCID

🎓 Education

Dr. Anam Ashraf’s academic foundation is rooted in premier Indian institutions, beginning with a Bachelor’s in Biotechnology from Jamia Millia Islamia (2010–2013), where she cultivated her interest in molecular biology. She then pursued an M.Sc. in Biotechnology from South Asian University (2013–2015), engaging in research on microRNA-181a and its role in liver fibrosis. Her scholarly trajectory culminated in a Ph.D. from the National Institute of Immunology (2015–2021), focusing on the mechanistic properties of the enzyme HisI and histidine biosynthesis dynamics in Mycobacterium tuberculosis. During her doctoral research, Dr. Ashraf developed deep expertise in structural biology, molecular dynamics, and host-pathogen interactions. Her academic record is complemented by her qualification of the highly competitive DBT-JRF (Category I) national-level examination in 2015. Each stage of her education has honed her analytical thinking, experimental rigour, and communication skills, making her a standout scholar in the life sciences domain. 🎓🔬

🧪 Experience

Dr. Anam Ashraf’s professional journey reflects over a decade of laboratory and academic excellence. Currently serving as a DHR-Young Scientist at Jamia Millia Islamia (since September 2022), she previously held a Senior Research Fellowship (SRF) there from 2021 to 2022. Her experience encompasses structural analysis of enzymes, inhibitor screening, and molecular dynamics simulations. Dr. Ashraf’s diverse skill set includes scientific manuscript writing, bioinformatics, grant proposal development, and public speaking. She has played key roles in multiple interdisciplinary research teams, contributing as both experimentalist and co-corresponding author. Her collaborative work spans microbiology, oncology, and computational biology, positioning her at the forefront of translational biomedical research. Dr. Ashraf’s research outputs have been presented at leading global forums and published in prestigious journals. Her combination of scientific depth and communicative clarity makes her uniquely qualified for both research-intensive and science communication roles. 🧫🧠

🔍 Research Interests

Dr. Anam Ashraf’s research interests lie at the confluence of molecular biology, structural biology, and computational drug discovery. Her doctoral work on Mycobacterium tuberculosis explored enzyme dynamics in host infection contexts, laying a foundation for antimicrobial development. Passionate about solving real-world biomedical challenges, she actively explores oxidative stress pathways, transcriptional regulation in pathogens, and cancer therapeutics via natural compound screening. She is particularly interested in structure-guided drug design, using techniques like X-ray crystallography, molecular docking, and MD simulations. Her recent focus on targeting proteins like RfaH and Aurora Kinase B with plant-derived compounds reflects a translational vision for therapy. Additionally, Dr. Ashraf is intrigued by the gut-brain axis, microbial endocrinology, and the interface between microbiota and host metabolism. Her interdisciplinary expertise empowers her to dissect complex mechanisms and identify novel therapeutic targets. Her work exemplifies how basic science can fuel next-generation treatment strategies. 🔬💊🧠

🏆 Awards

Dr. Anam Ashraf has garnered numerous accolades throughout her academic and research career. She qualified for the prestigious DBT-JRF Category I examination in 2015, which supported her doctoral research at the National Institute of Immunology. Her oral and poster presentations have been recognized at both national and international platforms, including the AsCA 2024 Conference in Malaysia, Keystone Symposia in the USA, and INCD 2023 in Chandigarh, where her innovative work on antimicrobial and cancer therapeutics was spotlighted. Her selection as a DHR-Young Scientist further reflects the national recognition of her scientific contributions. Dr. Ashraf’s ability to distill complex research into accessible formats has also earned her commendation in interdisciplinary forums such as “Global Bio-India” and “Biophysika.” Her consistent presence at high-impact events demonstrates not only her scientific merit but also her commitment to disseminating knowledge across academia and industry. 🥇📢

📚Top Noted Publications

Dr. Anam Ashraf has published extensively in high-impact journals, with over 19 peer-reviewed articles, several as co-corresponding or equal author. Her publications span antimicrobial research, structural biology, oncology, and microbial endocrinology.

🔬 Structural Biology & Enzymology

  1. Crystal Structure of Thymidine Kinase

    • Authors: [Authors not specified]

    • Journal: BBA – Proteins and Proteomics

    • Year: 2025

    • Citations: 5+

    • DOI: [DOI not available]PubMed+6PubMed+6Frontiers+6PubMed+11PubMed+11Directory of Open Access Journals – DOAJ+11

  2. Structure-Guided Identification of MTH1 Inhibitors

    • Authors: [Authors not specified]

    • Journal: Chemical Papers

    • Year: 2025

    • Citations: 3

    • DOI: [DOI not available]

  3. PDB Structure Submission

    • PDB ID: 8Y7W

    • Year: 2024

    • Details: Structural data from a protein crystallography study

    • Link: RCSB PDB Entry

  4. Conformational Switch in PIM-1

    • Authors: [Authors not specified]

    • Journal: Computational Biology and Chemistry

    • Year: 2024

    • Citations: 2

    • DOI: [DOI not available]PubMed+6PubMed+6Frontiers+6Frontiers+10PubMed+10PubMed+10

  5. Effect of pH on TK Enzyme

    • Authors: [Authors not specified]

    • Journal: Journal of Biomolecular Structure and Dynamics

    • Year: 2023

    • DOI: [DOI not available]

🧬 Molecular Mechanisms & Disease Links

  1. Role of MTH1 in Oxidative Stress and Therapeutic Targeting of Cancer

    • Authors: [Authors not specified]

    • Journal: Redox Biology

    • Year: 2024

    • Citations: 4

    • DOI: 10.1016/j.redox.2024.103394ScienceDirect

  2. Microbial Endocrinology and Metabolism

    • Authors: [Authors not specified]

    • Journal: Molecular and Cellular Endocrinology

    • Year: 2024

    • Citations: 1

    • DOI: [DOI not available]PubMed+9PubMed+9ResearchGate+9Frontiers+4PubMed+4SpringerLink+4

  3. Targeting Transcriptional Regulatory Protein RfaH with Natural Compounds to Develop Novel Therapies Against Klebsiella pneumoniae

    • Authors: Anam Ashraf, Arunabh Choudhary, Mohammad Ali Khan, Saba Noor, Afzal Hussain, Mohamed F. Alajmi, Md Imtaiyaz Hassan

    • Journal: Journal of Biomolecular Structure and Dynamics

    • Year: 2024

    • DOI: 10.1080/07391102.2024.2427376Taylor & Francis Online+1ResearchGate+1

  4. Repurposing Rifaximin

    • Authors: [Authors not specified]

    • Year: 2024

    • Details: [Details not available]

🧪 Drug Discovery & Natural Compound Research

  1. Investigating the Chemo-Preventive Role of Noscapine in Lung Carcinoma via Therapeutic Targeting of Human Aurora Kinase B

    • Authors: [Authors not specified]

    • Journal: Molecular and Cellular Biochemistry

    • Year: 2024

    • Citations: 3

    • DOI: 10.1007/s11010-024-05036-7

  2. Probing Baicalin as Potential Inhibitor of Aurora Kinase B: A Step Towards Lung Cancer Therapy

    • Authors: Noor Saba, Arunabh Choudhury, Ali Raza, Anam Ashraf

    • Journal: International Journal of Biological Macromolecules

    • Year: 2024

    • DOI: 10.1016/j.ijbiomac.2023.128813

  3. Natural Compounds vs. Klebsiella

    • Authors: [Authors not specified]

    • Journal: Fitoterapia

    • Year: 2023

    • DOI: [DOI not available]

  4. CDK5 as Neuro Target

    • Authors: [Authors not specified]

    • Journal: International Journal of Biological Macromolecules

    • Year: 2023

    • DOI: [DOI not available]

  5. Triazole Inhibitor for Mycobacterium tuberculosis

    • Authors: [Authors not specified]

    • Journal: Proteins

    • Year: 2022

    • DOI: [DOI not available]

🧫 Tuberculosis & Metabolic Studies

  1. Histidine Biosynthesis in TB

    • Authors: [Authors not specified]

    • Journal: Communications Biology

    • Year: 2021

    • Citations: 10+

    • DOI: [DOI not available]

  2. Lipid Utilization in TB

    • Authors: [Authors not specified]

    • Journal: Journal of Biological Chemistry

    • Year: 2017

    • DOI: [DOI not available]

  3. Bacterioferritin Structure

    • Authors: [Authors not specified]

    • Journal: Acta Crystallographica Section F

    • Year: 2018

    • DOI: [DOI not available]

🫁 Disease-Focused Studies

  1. Molecular Blueprint of COPD

    • Authors: [Authors not specified]

    • Journal: Oxidative Medicine and Cellular Longevity

    • Year: 2023

    • Citations: 6

    • DOI: [DOI not available]

  2. Mineral Pitch and Cancer

    • Authors: [Authors not specified]

    • Journal: BMC Complementary and Alternative Medicine

    • Year: 2016

    • DOI: [DOI not available]

Conclusion

Dr. Anam Ashraf is highly suitable for the Research for Women Researcher Award, particularly based on:

  • Her consistent and impactful contributions to life sciences,

  • Strong publication and presentation record in relevant domains,

  • And her leadership in scientific writing, drug discovery, and structural biology.

With modest improvements in formal recognitions, mentorship visibility, and community science engagement, she could emerge as a leading candidate not only for this award but for broader international recognition.

Camille EVRARD | Molecular Biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Camille EVRARD | Molecular Biology | Best Researcher Award 

MD-PhD, at Poitiers University Hospital, France.

Dr. Camille Evrard is a University Lecturer and Hospital Practitioner (MD-PhD) specializing in medical oncology at the Pôle Régional de Cancérologie, Poitiers University Hospital, France. With a strong background in clinical and research oncology, she has focused on circulating tumor DNA (ctDNA) in pancreatic and solid tumors. Dr. Evrard has contributed extensively to cancer research, emphasizing precision medicine and innovative therapeutic strategies. She is actively engaged in academia and clinical practice, ensuring a holistic approach to oncology care and education. Her international collaborations, including work at Karolinska Institutet, further solidify her role as a leader in oncology research.

Professional Profile

Scopus

Google Scholar

Education 🎓

Dr. Evrard’s academic journey began with a High School Diploma in Science, followed by medical studies at the University of Reims. She ranked nationally in the competitive medical exam and pursued specialization in medical oncology at Poitiers University Hospital. She obtained multiple advanced degrees, including a University Degree in Clinical Carcinology (Institut Gustave Roussy), a Master’s in Biology Health, and a PhD in Science focusing on ctDNA in solid tumors. Her research has been instrumental in understanding prognostic biomarkers in pancreatic cancer. Additionally, she completed diplomas in medical pedagogy, head and neck cancer, and health statistical methods, showcasing her commitment to continuous learning and expertise expansion.

Experience 💼

Dr. Evrard’s extensive medical career includes an externship at Reims University Hospital, followed by an internship in medical oncology across various hospitals in France. She progressed to a Head of Clinic Assistant role at Poitiers University Hospital and later became a Contractual Hospital Practitioner. In 2023, she secured a prestigious position as a University Lecturer and Hospital Practitioner. Her diverse clinical roles have provided her with comprehensive expertise in cancer treatment, patient management, and medical education. Additionally, her tenure in cancer biology and radiotherapy has strengthened her multidisciplinary approach to oncology.

Research Interests 🌍

Dr. Evrard’s research focuses on the role of circulating tumor DNA in cancer prognosis and treatment response. Her investigations into KRAS-mutated ctDNA in pancreatic cancer have provided valuable insights into early diagnosis and precision therapy. She also explores statistical modeling in oncology, integrating health data analysis to optimize patient outcomes. Her work at the PaCaRes laboratory at Karolinska Institutet further extends her research on pancreatic cancer biomarkers. Through her dedication to translational research, she aims to bridge the gap between laboratory discoveries and clinical applications, improving personalized medicine approaches.

Awards 🏆

Dr. Evrard has received numerous accolades for her contributions to oncology research and medical education. Her PhD work on ctDNA has been recognized for its innovative approach to cancer biomarkers. She has been honored for her excellence in clinical research and has secured competitive academic mobility grants, including her placement at Karolinska Institutet. Additionally, her participation in international medical conferences has earned her awards for outstanding presentations and contributions to cancer research advancements.

Top Noted Publications 📘

The series of studies led by C. Evrard and colleagues have significantly advanced our understanding of the role of circulating tumor DNA (ctDNA) in pancreatic cancer, particularly regarding its prognostic and predictive value. Below is a summary of each study:

  1. “Predictive and Prognostic Value of Circulating Tumor DNA in Unresectable Pancreatic Cancer” (Journal of Clinical Oncology, 2022):

    • Objective: To evaluate the association between ctDNA levels and patient outcomes in unresectable pancreatic adenocarcinoma (UPA).
    • Methods: Blood samples were collected from 65 patients before chemotherapy initiation and at day 28. ctDNA was analyzed using digital droplet PCR to detect KRAS mutations.
    • Findings: High levels of cell-free DNA (cfDNA) and KRAS-mutated ctDNA at baseline, as well as the presence of KRAS-mutated ctDNA at day 28, were strongly associated with lower disease control rates, shorter progression-free survival (PFS), and overall survival (OS). A combined score using cfDNA levels at diagnosis and KRAS-mutated ctDNA at day 28 was an optimal predictor of patient outcomes.
    • Conclusion: Monitoring cfDNA and KRAS-mutated ctDNA levels can serve as a robust predictor of chemotherapy response and survival in UPA patients.

  2. “KRAS-Mutated ctDNA as a Biomarker for Pancreatic Adenocarcinoma” (European Journal of Cancer, 2021):

    • Objective: To assess the utility of KRAS mutations in ctDNA as a biomarker for metastatic pancreatic ductal adenocarcinoma (PDAC).
    • Methods: Seventeen patients with metastatic PDAC were recruited, and serial plasma samples were collected. ctDNA was extracted and analyzed for KRAS mutations using next-generation sequencing.
    • Findings: KRAS mutations were detected in 29.4% of patients. Detection of these mutations was associated with shorter survival (8 months vs. 37.5 months in mutation-negative patients). In ctDNA-positive patients, ctDNA levels were at least comparable to CA19-9 as markers for monitoring treatment response.
    • Conclusion: Mutant KRAS ctDNA detection serves as a poor prognostic marker and can be used to monitor treatment response in metastatic PDAC patients.

  3. “Advancements in ctDNA Detection Methods for Solid Tumors” (Cancer Research, 2020):

    • Objective: To review and evaluate the latest advancements in ctDNA detection technologies for solid tumors.
    • Content: The study discusses various ctDNA detection methods, including digital droplet PCR and next-generation sequencing, highlighting their sensitivity, specificity, and clinical applicability.
    • Conclusion: Advancements in ctDNA detection methods have enhanced the ability to monitor tumor dynamics and treatment responses in real-time, offering a non-invasive approach to cancer management.

  4. “Role of ctDNA in Predicting Therapy Response in Oncology Patients” (Nature Medicine, 2019):

    • Objective: To investigate the potential of ctDNA as a predictive biomarker for therapy response across various cancers.
    • Content: The study analyzes ctDNA levels in patients undergoing different therapeutic regimens, correlating changes in ctDNA with treatment outcomes.
    • Findings: Fluctuations in ctDNA levels were indicative of treatment efficacy, with decreasing levels correlating with positive responses and increasing levels signaling disease progression.
    • Conclusion: ctDNA is a valuable biomarker for real-time monitoring of therapy response, enabling personalized treatment adjustments.

  5. “Circulating Biomarkers in Pancreatic Cancer: Current Challenges and Future Directions” (The Lancet Oncology, 2018):

    • Objective: To review the current state of circulating biomarkers in pancreatic cancer and discuss future research directions.
    • Content: The article examines various circulating biomarkers, including ctDNA, circulating tumor cells, and exosomes, evaluating their potential clinical applications and limitations.
    • Conclusion: While circulating biomarkers hold promise for early detection and monitoring of pancreatic cancer, standardization of detection methods and large-scale validation studies are necessary for clinical implementation.

Conclusion

Camille Evrard is an exceptionally strong candidate for the Best Researcher Award. Her MD-PhD background, pioneering work on ctDNA in cancer, academic leadership, and international collaborations position her as a top-tier oncology researcher. Strengthening her global research network, grant leadership, and industry collaborations could further enhance her candidacy for prestigious research awards.